AstraZeneca has officially opened a new Active Pharmaceutical Ingredient manufacturing facility in Dublin, deploying advanced automation, artificial intelligence, and innovative technologies to push the boundaries of pharmaceutical science and manufacturing, according to IDA Ireland.

The facility was developed with the support and collaboration of IDA Ireland and is designed to play a key role in the development and commercial launch of AstraZeneca's new medicines across its oncology portfolio and beyond.

Pam Cheng, Executive Vice President of Global Operations, IT and Chief Sustainability Officer at AstraZeneca, said: "This cutting-edge API Commercialisation facility is an innovative and unique asset in our global operations network, and plays a key role in the development and launch of our new medicines across our oncology portfolio and beyond. Through advanced automation, AI and innovative new technologies, we're pushing the boundaries of science and manufacturing enhancing speed, flexibility, and sustainability to deliver future therapies to patients."

Michael Lohan, chief executive of IDA Ireland, said the investment underlines Ireland's strength in advanced manufacturing, innovation, and talent, and strengthens the resilience of global supply chains while delivering life-changing medicines for patients worldwide.

The Dublin facility represents a significant addition to AstraZeneca's global operations network, reinforcing Ireland's position as a leading destination for high-value pharmaceutical manufacturing investment within the life sciences sector.

API manufacturing is a critical and technically complex segment of pharmaceutical production, forming the foundation of finished drug products across therapeutic areas including oncology, where AstraZeneca has established a significant global commercial presence.

The opening further consolidates Dublin's role as a hub for advanced biopharma manufacturing, attracting sustained investment from global pharmaceutical companies seeking to strengthen supply chain resilience and manufacturing innovation.

Access the full report for further detail on AstraZeneca's new Dublin API facility and its role in the company's global operations network.